What the Study Found (In Plain English)
Published in Journal of clinical pharmacology (2021), this phase iii randomized trial evaluating human clinical outcomes investigated: The selective T-cell costimulation modulator abatacept is approved for treatment of adult rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA; 6-17 years [intravenous] and 2-17 years [subcutaneous]). Key clinical takeaway: C minss was the best exposure predictor for the JIA-ACR response: log odds for response increased in proportion to log-transformed C minss ; JIA-ACR30 approached a plateau when C minss ≥ 10 μg/mL.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of clinical pharmacology, 2021-05-15; Phase III Randomized Trial; Rigor 82/100): C minss was the best exposure predictor for the JIA-ACR response: log odds for response increased in proportion to log-transformed C minss ; JIA-ACR30 approached a plateau when C minss ≥ 10 μg/mL.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.